Innova Captab

884.20
-26.75
(-2.94%)
Market Cap
5,059.83 Cr
EPS
18.66
PE Ratio
41.03
Dividend Yield
0.00 %
Industry
Healthcare
52 Week High
1,260.00
52 Week Low
421.35
PB Ratio
5.84
Debt to Equity
0.38
Add Ratio
hide

Investment Returns

In Long Term
In Short Term
1 Year
0.00%
2 Years
0.00%
3 Years
0.00%
4 Years
0.00%
5 Years
0.00%
Analyst Rating
- By Refinitiv from2 analysts
BUY
Analysts have suggested that investors can buy this stock
Buy
Buy+100.00 %
+100.00 %
Hold
Hold0.0 %
0.0 %
Sell
Sell0.0 %
0.0 %
Competitors LTP Market Cap (₹ Cr.) P/E Ratio Revenue (₹ Cr.) YoY Revenue Growth % Net Profit (₹ Cr.) YoY Profit Growth % RSI
1,787.40
#1 4,28,857.13
36.71
#1 49,887.20
12.06
#1 9,648
13.77
59.27
6,012.50
1,59,612.98
79.83
8,184.00
0.89
1,600
#1 64.53
57.99
1,525.90
1,23,233.96
25.11
26,520.70
14.17
4,155
47.38
57.43
3,238.90
1,09,619.09
60.42
10,785.70
11.59
1,656
13.54
52.37
2,557.50
1,05,516.96
52.60
10,615.60
19.57
1,942
-16.38
59.98
1,174.80
98,031.82
#1 18.66
28,905.40
12.36
5,578
1.69
54.12
2,019.60
92,203.01
33.50
20,141.50
#1 19.94
1,936
38.82
50.28
859.65
86,500.90
19.53
19,831.50
13.82
3,831
29.92
46.44
1,220.10
70,863.61
20.72
29,559.20
17.55
3,169
-10.04
58.85
29,705.00
63,121.05
47.82
6,097.20
10.80
1,201
16.01
45.94
Growth Rate
Revenue Growth
16.91 %
Net Income Growth
38.68 %
Cash Flow Change
118.03 %
ROE
-53.82 %
ROCE
-45.34 %
EBITDA Margin (Avg.)
16.22 %

Quarterly Financial Results

Quarterly Financials
Mar 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Revenue
217
244
245
244
234
286
305
268
296
320
321
Expenses
197
211
208
214
202
243
258
225
252
269
270
EBITDA
21
33
37
29
32
44
47
44
44
52
51
Operating Profit %
9 %
13 %
14 %
11 %
13 %
14 %
15 %
15 %
14 %
16 %
15 %
Depreciation
3
3
3
3
3
5
5
3
5
5
5
Interest
3
5
6
5
5
9
7
1
0
0
0
Profit Before Tax
15
25
28
21
25
30
35
40
39
47
46
Tax
2
6
9
4
7
7
10
11
10
12
11
Net Profit
13
19
20
17
18
23
25
29
30
35
34
EPS in ₹
108.91
3.91
4.08
3.59
3.67
4.77
4.39
5.02
5.15
6.12
5.97

Balance Sheet

Balance Sheet
2019
2020
2021
2022
2023
2024
Total Assets
223
245
370
576
704
1,321
Fixed Assets
79
73
79
183
183
358
Current Assets
143
171
271
379
443
580
Capital Work in Progress
0
0
7
0
22
341
Investments
0
0
0
0
0
0
Other Assets
145
172
283
392
500
622
Total Liabilities
223
245
370
576
704
1,321
Current Liabilities
112
120
215
295
278
266
Non Current Liabilities
28
14
10
72
150
225
Total Equity
83
110
145
209
277
831
Reserve & Surplus
71
98
133
197
229
774
Share Capital
12
12
12
12
48
57

Cash Flow

Cash Flow
2019
2020
2021
2022
2023
2024
Net Cash Flow
1
2
3
-5
3
8
Investing Activities
-9
-6
-20
-188
-91
-499
Operating Activities
19
31
42
59
67
146
Financing Activities
-9
-23
-19
125
27
361

Share Holding

% Holding
Jun 2022
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Promoter
69.75 %
50.90 %
50.90 %
50.90 %
50.90 %
50.90 %
50.90 %
50.90 %
FIIs
0.00 %
0.00 %
0.00 %
1.94 %
1.19 %
1.01 %
0.74 %
0.34 %
DIIs
0.00 %
11.73 %
4.98 %
20.77 %
21.23 %
20.61 %
19.96 %
19.76 %
Government
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
Public / Retail
0.00 %
32.10 %
32.29 %
25.47 %
25.80 %
26.00 %
26.96 %
27.62 %
Others
30.25 %
5.26 %
11.83 %
0.91 %
0.88 %
1.48 %
1.45 %
1.37 %
No of Share Holders
7
1,39,154
1,39,154
39,396
35,115
32,254
36,692
39,996

Dividend History

Dividends per share (FY)
Dividend yield (FY) %
Dividends per share (FY)
Dividend yield (FY) %

No dividends have been distributed by the company in the past 10 years

Corporate Action

Announcements

Announcement under Regulation 30 (LODR)-Monitoring Agency Report1 day ago
Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Apr 12, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Apr 07, 2025
Closure of Trading WindowMar 27, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMar 19, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMar 17, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMar 01, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 26, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 26, 2025
Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015.Feb 14, 2025
Announcement under Regulation 30 (LODR)-Earnings Call TranscriptFeb 13, 2025
Announcement under Regulation 30 (LODR)-Monitoring Agency ReportFeb 11, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationFeb 06, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeFeb 06, 2025
Integrated Filing (Financial)Feb 05, 2025
Statement For Deviation(S) Or Variation(S) Pursuant To Regulation 32 Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations 2015 For The Quarter EnFeb 05, 2025
Announcement under Regulation 30 (LODR)-Investor PresentationFeb 05, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseFeb 05, 2025
Approval Of The Un-Audited (Standalone And Consolidated) Financial Results For The Quarter And Nine Months Ended December 31 2024Feb 05, 2025
Integrated Filing (Financial)Feb 05, 2025
Board Meeting Outcome for Outcome Of The Board Meeting Held Today I.E. February 05 2025Feb 05, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJan 30, 2025
Board Meeting Intimation for Intimation Of Board Meeting Under Regulation 29 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 For Consideration Of Un-Audited Financial ReJan 29, 2025
Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 - Sale Of Property Of Sharon Bio-Medicine Limited Material Subsidiary Of The Company.Jan 20, 2025
Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 -Shifting Of Registered Office Of Sharon Bio-Medicine Limited Material Subsidiary Of The CompaJan 20, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJan 14, 2025
Disclosure under Regulation 30A of LODRJan 14, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jan 06, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationDec 02, 2024
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationNov 23, 2024
Announcement under Regulation 30 (LODR)-Earnings Call TranscriptNov 14, 2024
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationNov 12, 2024
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationNov 12, 2024
Announcement under Regulation 30 (LODR)-Monitoring Agency ReportNov 11, 2024
Announcement under Regulation 30 (LODR)-Newspaper PublicationNov 08, 2024
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeNov 08, 2024
Statement For Deviation(S) Or Variation(S) Pursuant To Regulation 32 Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations, 2015 For The Quarter And Half Year Ended September 30, 2024Nov 07, 2024
Announcement under Regulation 30 (LODR)-Investor PresentationNov 07, 2024
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseNov 07, 2024
Approval Of The Un-Audited (Standalone And Consolidated) Financial Results For The Quarter And Half Year Ended September 30, 2024.Nov 07, 2024
Board Meeting Outcome for Outcome Of The Board Meeting Held Today I.E. November 07, 2024.Nov 07, 2024
Pursuant To The Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015, ('Listing Regulations'), We Wish To Inform You That Our Upcoming Jammu Facility Received 'Drug Manufacturing License' Vide Letter No. CLJK202406146 Dated November 06, 2024 From Government Of Jammu And Kashmir, Department Of Health And Medical Education, Drug Control Organisation, Jammu.Nov 06, 2024
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationOct 29, 2024
Board Meeting Intimation for Intimation Of Board Meeting Under Regulation 29 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 For Consideration Of Un-Audited Financial Results For The Quarter And Half Year Ended September 30, 2024.Oct 29, 2024
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018Oct 05, 2024
Closure of Trading WindowSep 26, 2024
Shareholder Meeting / Postal Ballot-Scrutinizer''s ReportSep 19, 2024
Shareholder Meeting / Postal Ballot-Outcome of AGMSep 18, 2024
Announcement under Regulation 30 (LODR)-Credit RatingAug 29, 2024
Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 25, 2024

Technical Indicators

RSI(14)
Neutral
51.06
ATR(14)
Volatile
46.77
STOCH(9,6)
Neutral
77.33
STOCH RSI(14)
Neutral
74.43
MACD(12,26)
Bullish
0.82
ADX(14)
Weak Trend
17.85
UO(9)
Bearish
49.57
ROC(12)
Uptrend And Accelerating
1.47
WillR(14)
Neutral
-25.71